SCHEMBL3535412

SCHEMBL3535412

Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NC(C)(C)C)cn1

nearest known ligand 0.77

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 14/20 0.77
CYP2C9 P11712 11/20 0.77
MAPK11 Q15759 3/20 0.77
BUB1 O43683 1/20 0.77
PRKACG P22612 1/20 0.77
MAPKAPK2 P49137 1/20 0.77
ACSL5 Q9ULC5 1/20 0.77
STK24 Q9Y6E0 1/20 0.77
MAPK13 O15264 6/20 0.50
RET P07949 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3409067 0.93 MAPK14 (0.82) MAPK14CYP2C9MAPK11BUB1PRKACG
SCHEMBL3406947 0.90 MAPK14 (0.75) MAPK14CYP2C9MAPK11BUB1PRKACG
SCHEMBL3405303 0.90 MAPK14 (0.75) MAPK14CYP2C9MAPK11BUB1PRKACG
SCHEMBL3408716 0.89 MAPK14 (0.78) MAPK14CYP2C9MAPK11BUB1PRKACG
SCHEMBL3410765 0.89 MAPK14 (0.78) MAPK14CYP2C9MAPK11BUB1PRKACG
SCHEMBL3404778 0.89 MAPK14 (0.74) MAPK14CYP2C9MAPK11BUB1PRKACG
SCHEMBL3428207 0.89 MAPK14 (0.70) MAPK14CYP2C9MAPK11BUB1PRKACG
SCHEMBL3428211 0.89 MAPK14 (0.70) MAPK14CYP2C9MAPK11BUB1PRKACG
SCHEMBL20448647 0.89 MAPK14 (0.76) MAPK14CYP2C9MAPK11BUB1PRKACG
SCHEMBL3405520 0.87 MAPK14 (0.74) MAPK14CYP2C9MAPK11BUB1PRKACG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10550073-B2 Benzamide derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2020-02-04 US disclosed
EP-1654235-B1 3- AMINOCARBONYL, 6-PHENYL SUBSTITUTED PYRIDINE-1-OXIDES AS P38 KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2012-12-26 EP disclosed
US-7838540-B2 3-aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2010-11-23 US disclosed
US-20070161684-A1 3-Aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors SIMITHKLINE BEECHMAN CORPORATION (US) 2007-07-12 US disclosed
EP-1654235-A1 3- AMINOCARBONYL, 6-PHENYL SUBSTITUTED PYRIDINE-1-OXIDES AS P38 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2006-05-10 EP disclosed
WO-2005014550-A1 3- AMINOCARBONYL, 6-PHENYL SUBSTITUTED PYRIDINE-1-OXIDES AS P38 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161684-A1 3-Aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors MAPK1, MAPK3, MAPKAPK2 MAPK14 34/4885CYP2C9 914/4885MAPK11 38/4885
US-10550073-B2 Benzamide derivative CYP3A5, ABCB1, CYP2D6 MAPK14 3791/4885CYP2C9 36/4885MAPK11 4212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.